Publications
Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort
Dresse MT, Ferreira PCL, Prasadan A, Diaz JL, Zeng X, Bellaver B, Povala G, Villemagne VL, Kamboh MI, Cohen AD, Pascoal TA, Ganguli M, Snitz BE, Shaaban CE, Karikari TK. Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort....
Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the community
Sehrawat A, Zeng X, Abrahamson EE, Deek RA, Gogola A, Kamboh MI, Pascoal TA, Villemagne VL, Lopez OL, Ikonomovic MD, Snitz BE, Cohen AD, Karikari TK. Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the...
Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer’s disease
Gogola A, Zeng X, Williams LA, Chapple-McGruder T, Saeed A, Lopresti BJ, Snitz B, Tudorascu D, Minhas D, Ikonomovic MD, Kofler J, Matan C, Pascoal TA, Aizenstein H, Zetterberg H, Blennow K, Lopez O, Villemagne VL, Karikari TK, Cohen AD. Impact of racialization on...
Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease
Rohden F, Ferreira PCL, Bellaver B, Ferrari-Souza JP, Aguzzoli CS, Soares C, Abbas S, Zalzale H, Povala G, Lussier FZ, Leffa DT, Bauer-Negrini G, Rahmouni N, Tissot C, Therriault J, Servaes S, Stevenson J, Benedet AL, Ashton NJ, Karikari TK, Tudorascu DL, Zetterberg...
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease
Abbas S, Ferreira PCL, Bellaver B, Povala G, Rohden F, Aguzzoli CS, Zalzale H, Ferrari-Souza JP, Leffa DT, Lussier FZ, Soares C, Bauer-Negrini G, Oliveira-Junior MS, Rodrigues MS, Saha P, Ruppert E, Medeiros MS, Tissot C, Therriault J, Rahmouni N, Servaes S, Benedet...
Equivalence of Plasma and Serum for Clinical Measurement of p-tau217: Comparative Analyses of Four Blood-Based Assays
Chen Y, Albert AL, Sehrawat A, Farinas M, Lopez OL, Zeng X, Cohen AD, Karikari TK. Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays. medRxiv [Preprint]. 2024 Dec 28:2024.12.26.24319657. doi:...
Loneliness and Biomarkers of Alzheimer’s Disease, Axonal Damage, and Astrogliosis: A Coordinated Analysis of Two Longitudinal Cohorts
Terracciano A, Walker KA, An Y, Bilgel M, Sutin AR, Luchetti M, Karakose S, Stephan Y, Blennow K, Zetterberg H, Ashton NJ, Karikari TK, Kac PR, Moghekar AR, Thambisetty M, Ferrucci L, Resnick SM. Loneliness and Biomarkers of Alzheimer's Disease, Axonal Damage, and...
Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits
Sewell KR, Oberlin LE, Karikari TK, Olvera-Rojas M, Wan L, Morris JK, Kueck PJ, Zeng X, Huang H, Grove G, Chen Y, Lafferty TK, Sehrawat A, Kamboh MI, Marsland AL, Kramer AF, McAuley E, Burns JM, Hillman CH, Vidoni ED, Kang C, Erickson KI. Blood biomarkers...
Proteomic signatures of corona and herpes viral antibodies identify IGDCC4 as a mediator of neurodegeneration
Duggan MR, Yang S, Gomez GT, Cui Y, Capuano AW, Chen J, Yang Z, Wen J, Erus G, Drouin SM, Zweibaum D, Tian Q, Candia J, Bilgel M, Lewis A, Moghekar A, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Maher BS, Spira AP, Dumitrescu L, Hohman TJ, Gottesman RF,...
Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer’s disease
Bellaver B, Povala G, Ferreira PCL, Bauer-Negrini G, Lussier FZ, Leffa DT, Ferrari-Souza JP, Rodrigues MS, Amaral L, Oliveira MS, Soares C, Rocha A, Saha P, Rahmouni N, Macedo A, Tissot C, Therriault J, Servaes S, Klostranec J, Montembeault M, Benedet AL, Ashton NJ,...
Dissection of blood–brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disorders
Vrillon A, Ashton NJ, Bouaziz-Amar E, Mouton-Liger F, Cognat E, Dumurgier J, Lilamand M, Karikari TK, Prevot V, Zetterberg H, Blennow K, Paquet C. Dissection of blood-brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF...
Sex differences on tau, astrocytic, and neurodegenerative plasma biomarkers
Labonte J, Sugarman MA, Pettway E, Zetterberg H, Blennow K, Ashton NJ, Karikari TK, Aparicio HJ, Frank B, Tripodis Y, Martin B, Palmisano JN, Steinberg EG, Simkin I, Farrer LA, Jun GR, Turk KW, Budson AE, O'Connor MK, Au R, Goldstein LE, Stern RA, Stein TD, McKee AC,...
Tau profiling across Alzheimer’s disease staging reveals vulnerability to disease pathophysiology
Bezgin G, Pascoal TA, Therriault J, Lussier FZ, Servaes S, Kang MS, Savard M, Tissot C, Stevenson J, Wang YT, Ottoy J, Rahmouni N, Fernandez-Arias J, Hosseini SA, Aumont É, Hall B, Poltronetti NM, Pallen V, Benedet AL, Ashton NJ, Blennow K, Zetterberg H, Karikari TK,...
Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer’s disease
Kac PR, Alcolea D, Montoliu-Gaya L, Fernández S, Rodriguez JL, Maure L, González-Ortiz F, Benejam B, Turton M, Barroeta I, Harrison P, Videla L, Ashton NJ, Lleó A, Zetterberg H, Carmona-Iragui M, Karikari TK, Fortea J, Blennow K. Plasma p-tau212 as a biomarker of...
The LATTICE Study: Design of a pilot feasibility randomized controlled trial of lithium to delay cognitive decline in mild cognitive impairment
Gildengers AG, Ibrahim TS, Zeng X, Aizenstein HJ, Alkhateeb SK, Anderson SJ, Chu C, Diaz JL, Emanuel JE, Karikari TK, Li J, Lopez OL, Lopresti BJ, Royse SK, Sajewski AN, Santini T, Weinstein AM, Wu M, Butters MA. The LATTICE Study: Design of a pilot feasibility...
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease
Abbas S, Ferreira PCL, Bellaver B, Povala G, Rohden F, Aguzzoli CS, Zalzale H, Ferrari-Souza JP, Leffa DT, Lussier FZ, Soares C, Bauer-Negrini G, Oliveira-Junior MS, Rodrigues MS, Saha P, Ruppert E, Medeiros MS, Tissot C, Therriault J, Rahmouni N, Servaes S, Benedet...
Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease
Islam T, Hill E, Abrahamson EE, Servaes S, Smirnov DS, Zeng X, Sehrawat A, Chen Y, Kac PR, Kvartsberg H, Olsson M, Sjons E, Gonzalez-Ortiz F, Therriault J, Tissot C, Del Popolo I, Rahmouni N, Richardson A, Mitchell V, Zetterberg H, Pascoal TA, Lashley T, Wall MJ,...
Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort
Zeng X, Sehrawat A, Lafferty TK, Chen Y, Rawat M, Kamboh MI, Villemagne VL, Lopez OL, Cohen AD, Karikari TK. Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse...
Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217/Aβ42
Olvera-Rojas M, Sewell KR, Karikari TK, Huang H, Oberlin LE, Zeng X, Morris JK, Collins AM, Drake JA, Sutton BP, Kramer AF, Hillman CH, Vidoni ED, Burns JM, Kamboh MI, McAuley E, Marsland AL, Chen Y, Lafferty TK, Sehrawat A, Jakicic JM, Wan L, Kang C, Erickson KI....
Dementia risk reduction in the African context: Multi-national implementation of multimodal strategies to promote healthy brain aging in Africa (the Africa-FINGERS project)
Udeh-Momoh CT, Maina R, Anazodo UC, Akinyemi R, Atwoli L, Baker L, Bassil D, Blackmon K, Bosire E, Chemutai G, Crivelli L, Eze LU, Ibanez A, Kafetsouli D, Karikari TK, Khakali L, Kumar M, Lengyel I, de Jager Loots CA, Mangialasche F, Mbugua S, Merali Z, Mielke M,...
Plasma phosphorylated-tau217 is increased in Niemann-Pick disease type C
Gonzalez-Ortiz, F., Karikari, T. K., Taylor-Te Vruchte, D., Shepherd, D., Kirsebom, B. E., Fladby, T., Platt, F., & Blennow, K. (2024). Plasma phosphorylated-tau217 is increased in Niemann-Pick disease type C. Brain communications, 6(6), fcae375....
Where Do Plasma Biomarkers fit in With Current Alzheimer’s Disease Detection?
Gildengers A, Weinstein AM, Gujral S, Zeng X, Diaz JL, Lafferty TK, Cowie M, Emanuel JE, Lopez O, Royse SK, Lopresti B, Karikari TK. Where Do Plasma Biomarkers fit in With Current Alzheimer's Disease Detection? Am J Geriatr Psychiatry. 2025 Apr;33(4):428-437. doi:...
Proteome-wide analysis identifies plasma immune regulators of amyloid-beta progression.
Duggan MR, Gomez GT, Joynes CM, Bilgel M, Chen J, Fattorelli N, Hohman TJ, Mancuso R, Cordon J, Castellano T, Koran MEI, Candia J, Lewis A, Moghekar A, Ashton NJ, Kac PR, Karikari TK, Blennow K, Zetterberg H, Martinez-Muriana A, De Strooper B, Thambisetty M, Ferrucci...
Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
Rabl M, Zullo L, Lewczuk P, Kornhuber J, Karikari TK, Blennow K, Zetterberg H, Bavato F, Quednow BB, Seifritz E, von Gunten A, Clark C, Popp J. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric...
Plasma Brain-Derived Tau in Prognosis of Large Vessel Occlusion Ischemic Stroke.
Varela R, Gonzalez-Ortiz F, Dias A, Knuth NL, Fonte J, Pinto B, Yuksekel I, Abreu V, Silva I, Igreja L, Lopes J, Silva J, Dias R, Filipe JP, Malaquias MJ, Moutinho A, Gabriel D, Aires A, Antunes R, Rocha JP, Felgueiras R, Almendra R, Castro P, Zetterberg H, Magalhães...
18F-Flortaucipir (AV1451) imaging identifies grey matter atrophy in retired athletes.
Vasilevskaya A, Anastassiadis C, Thapa S, Taghdiri F, Khodadadi M, Multani N, Rusjan P, Ozzoude M, Tarazi A, Mushtaque A, Wennberg R, Houle S, Green R, Colella B, Vasdev N, Blennow K, Zetterberg H, Karikari T, Sato C, Moreno D, Rogaeva E, Mikulis D, Davis KD, Tator C,...
Associations of endogenous estrogens, plasma Alzheimer’s disease biomarkers, and APOE4 carrier status on regional brain volumes in postmenopausal women.
Wugalter KA, Schroeder RA, Thurston RC, Wu M, Aizenstein HJ, Cohen AD, Kamboh MI, Karikari TK, Derby CA, Maki PM. Associations of endogenous estrogens, plasma Alzheimer's disease biomarkers, and APOE4 carrier status on regional brain volumes in postmenopausal women....